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EXPLANATION OF THESIS FORMAT 
The following thesis consists of a general introduction, a review of 
literature, two separate manuscripts (Sections I and II), and literature cited. The 
master's candidate, Donald Raymond Cook, is the senior author and principal 
investigator for each of the manuscripts. 
1 
GENERAL INTRODUCTION 
Pseudorabies is an infectious disease caused by pseudorabies virus 
(PRV), which is classified into the herpesvirus subfamily, Alphaherpesvirinae.72 
Herpesviruses have relatively large genetic potentials (SO to 100 genes)99 and 
complex life cycles, involving infection of multiple cell types and the 
establishment of latent infection within the host. Some PRV genes are not 
essential for replication and production of virus particles, particularly when the 
virus is propagated in cell cultures. It is possible for genetic mutation to create 
attenuated strains of virus, and this has occurred with high passages of virulent 
PRV in cell cultures81 and chicken embryos.56 A number of these attenuated 
strains of PRV have been evaluated as vaccines.8,9,18,63,90,95 They have been 
selected mainly on the basis of reduced virulence, without knowing the nature 
or stability of the underlying genetic alteration.59 Although vaccination based 
on these attenuated strains has been effective, there are some disadvantages to 
their use.73 Planned modifications to the PRV genome, using recombinant DNA 
technology, have been made to produce vaccine strains that overcome these 
disadvantages. The goal has been to produce vaccine strains that provide high 
levels of protection against disease, that are safe for all classes and ages of pigs, 
that have reduced virulence for other species, and that allow serological 
differentiation between vaccinated and field infected pigs.94 
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LITERATURE REVIEW 
Introduction 
The first scientific description of pseudorabies was by Aujeszky in 1902,6 
however, there is evidence to suggest that PRV has been present in the United 
States since the mid 1800s.43 Pigs are considered the reservoir host of PRV22,46 
and the only significant source of infection of other susceptible species. 
Pseudorabies has a wide host range including cattle, sheep, goats, dogs, cats, 
and raccoons, and in these species the disease is uniformly fatal.28,38,53 The 
disease in pigs is economically important, and characterized by abortions, 
neurological signs in piglets, and respiratory signs and growth retardation in 
growing pigs.105 Mortality due to PRV infection is greatest in baby pigs and 
least in mature pigs. The severity of infection is dependent on the virulence of 
the viral strain, age of the pigs, dose of virus and route of exposure.28 Prior to . 
the 1970s there were only sporadic reports of outbreaks of pseudorabies in pigs 
in the United States,80,87,89 however, in the first half of that decade the incidence 
of pseudorabies significantly increased.26,37 Slaughter survey serums collected 
in the United States in 1974 showed 0.56% of pigs were positive for PRV.29 By 
1978 the number of positives had increased to 3.73%.96 As pseudorabies was 
considered a serious threat to the pig industry, considerable attention was given 
to measures that would reduce losses to the disease.39 Attenuated and killed 
PRV vaccines were licensed for use in the United States in 1977 and 1978 
respectively,12,55 and federal regulations prohibiting the interstate movement of 
seropositive pigs were put into effect by 1979.12 
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Vaccination of pigs with killed or modified live virus is now commonly 
practiced, as it will reduce economic losses due to pseudorabies.24 The vaccines 
licensed. in the United States are shown in Table 1. Vaccination may help 
eliminate PRV from a pig herd by decreasing the shedding of virulent virus 
after challenge and reducing the spread of virus within a herd.22 However, it is 
not as effective in controlling pseudorabies as the elimination of infected pigs 
from the herd by test and removal procedures,97 so these methods are often 
used in combination. Vaccines reduce or prevent clinical signs in pigs exposed 
to PRV, but they do not prevent infection or the establishment of latent 
infections.70 Therefore, there is a need to assess PRV exposure in vaccinated 
pigs. The standard serological procedures used to detect PRV antibodies are of 
little value for this purpose. They cannot distinguish antibodies induced by 
natural infection with PRV from antibodies induced by PRV vaccines. 48 
Considerable effort has been directed at this problem, as the inability to 
differentiate these antibody responses markedly decreases the efficiency of 
eradication programs utilizing vaccination.101 The development of gene 
deleted vaccines and their associated diagnostic tests, specific for antibodies to 
the protein coded for by the deleted gene, makes the distinction possible.107 
Currently, the only gene deleted vaccine which has an accompanying USDA 
licensed diagnostic test is PRV /Marker®a. This vaccine utilizes a genetically 
engineered PRV strain in which the deletion of the gene coding for glycoprotein 
X acts as a "negative marker", allowing serological differentiation be~ ..... ..;n 
a Syntro Vet Incorporated, Lenexa, Kansas. 
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Table 1. Licensed Pseudorabies Vaccines at 1/1/89 
Accompanying Modified Live 
Vaccine Company Diagnostic Test (ML) /Killed (K) 
PRV /Marker® SyntroVet Inc. Yes ML 
PR-Vac® Norden Labs. No ML 
PR-Vac®-Killed Norden Labs. No K 
PR-Vac® /Leptoferm-5® Norden Labs. No ML 
Pseudorabies Vaccine Bio-Ceutic Labs. No ML 
Omnivac TM-PRV TechAmerica No ML 
Pseudovax Pitman-Moore No ML 
Tolvid® The Upjohn Co. No ML 
Suvaxyn ™-PRV Solvay Veterinary No K 
Porci-Rab® Beecham Labs. No K 
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vaccinated pigs and those infected with field virus.94 
In the following review of the literature on PRV, emphasis will be placed 
on the physic-chemical properties of the virus, the genetic variation between 
vaccine strains of PRV, vaccination of pigs against pseudorabies, and the 
humeral immune response in pigs induced by vaccine and natural exposure to 
PRV. 
Pseudorabies Virus 
The classification of PRV (Suid herpesvirus I) as a member of the family 
Herpesviridae is based on its physicochemical properties and strategy of 
replication.16,35,72 The PRV genome is a double stranded, linear DNA molecule 
with a molecular weight of 90X106 daltons.16 The nucleocapsid has a diameter 
of 150 to 186 nanometers as measured by electron microscopy.16 This is 
surrounded by an envelope consisting of a double or triple lipid containing 
membrane.23 Pseudorabies virus has further been classified into the subfamily 
Alphaherpesvirinae based on its variable host range, highly cytopathic nature, 
short replication cycle and frequent establishment of latent infection.72 
The genome of PRV consists of approximately 160 kbp,85 although this 
may vary due to major differences between wild and some vaccine strains of the 
virus.58 In recent years, there have been rapid advancements in the knowledge 
of the genomic structure of PRV. These advancements have come mainly from 
the study of mutant strains of PRV by using restriction 
endonucleases.16,17,69,76,77,79,108 There are 4 distinct regions of the genome: a 
unique long (UL) region of 65X106 daltons, an inverted repeat (IR) region and 
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terminal repeat (TR) region of 10X106 daltons each, and a unique short region 
of 6 X 106 daltons.16,17 
The number of polypeptides identified as being coded for by the PRV 
genome, has changed over time with advances in protein separation and 
resolution techniques.16 Of the 16 structural proteins identified, the virus 
envelope contains 4 major and 3 minor glycoproteins and 1 non-glycosylated 
protein.42,60 The other 8 are non-glycosylated proteins found in the 
nucleocapsid. 93 Mapping of PRV genomes has identified the locations of some 
of the genes that code for these proteins and also identified major genetic 
differences between strains. 
The unique short region of the PRV genome has had significant attention 
from researchers, as most avirulent strains used as vaccines, have genetic 
deletions in this region. The unique short region contains a cluster of 4 
glycoprotein genes, glycoprotein X (gpX),81glycoprotein50 (gp 50),108 
glycoprotein 63 (gp 63),77 and glycoprotein I (gp D.69 
The PRV strains used in PR-Vac®b and Pseudorabies Vaccinec do not 
code for gpI. 73 Glycoprotein I, is one of the minor envelope glycoproteins56 and 
plays a role in the virulence of PRV by being involved in the release of virions 
from some cell types.14 
Both genetically engineered strains of PRV used as vaccines in the United 
States, PRV /Marker® and Tolvid®d, have deletions of the gene coding for 
gpX.73,94,98 There is controversy whether or not gpX ~::; ~ ~lon-structural 
b Norden Laboratories, Lincoln, Nebraska. 
c Bio Ceutic Laboratories, St. Joseph, Missouri. 
d The Upjohn Company, Kalamazoo, Michigan. 
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glycoprotein. It is secreted from PRV infected cells and early workers reported 
that it did not form part of the enveloped virus.JS However, recent evaluation of 
the gpX gene sequence suggests that the primary translation product is 
probably a membrane protein with the usual hydrophilic cytoplasmic domain 
structure.13 There is a cellular form of gpX with a higher molecular weight than 
the form released from infected cells.13 There are no reports of naturally 
occurring PRV strains which lack the gpX gene, however, it is not essential for 
growth in cell cultures or replication within the host.99 As yet, the function of 
gpX has not been determined. 
The thymidine kinase (TI<) gene, located in the UL region of the genome, 
codes for an enzyme that provides the .virus with a thymidine utilization 
pathway independent of the cell thymidilate synthetase pathway.86 This TI< 
activity is not essential for growth of PRV in cell cultures;95 but appears 
important for virulence and latency.99 The TI< gene has been deleted from 
genetically engineered stains of PRV to reduce vaccine virulence and to lower 
the potential of vaccine strains to establish latent infections.73 
The PRV strain used in PRV /Marker® has additional alterations to its 
genome. Two small gene sequences have been deleted from the IR and TR 
regions to reduce virulence and a lactase gene has been inserted to allow rapid 
identification of isolates of this strain.37 
Pseudorabies Virus Vaccines 
The evaluation of a number of modified live pseudorabies virus 
(MLPRV) vaccines and killed pseudorabies virus (KPRV) vaccines have been 
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reported in the literature. There is considerable variation in the reported 
findings due mainly to difference in biological characteristics between the 
strains of PRV used in MLPRV vaccines, but also due to different methods 
employed for inactivation of the KPRV vaccines. 
Vaccination with MLPRV or KPRV will not prevent infection3,25,27,63,70 
or the establishment of latent infection with virulent PRV.70 Vaccination will 
prevent mortalities in piglets and reduce clinical signs, including fever, weight 
loss and central nervous system (CNS) dysfunction, after challenge 
exposure.3,25,27,70 It will also reduce virus dissemination after challenge 
exposure, but not prevent it.3,11,25,27,63 It is likely that a more limited range of 
organs are infected by virus in vaccinated animals and there is a reduction in 
virus replication in those organs that are infected.27 
Modified Live Vaccines 
Modified live virus vaccines generally require virus replication within 
the host animal in order to produce sufficient antigenic mass to stimulate the 
immune system.73 The replication and distribution of PRV in pigs, immunized 
intramuscularly (IM), is dependent on the strain and amount of virus 
used.11,27,63 The advantage of replication within the host is that generally a 
single dose of MLPRV is sufficient to produce a good immune response and 
proper immunization.3,18,25,27,63,90 Compared to KPRV vaccines, MLPRV 
vaccines have an advantage of inducing an immune response that may mimic 
that produced by natural infection in the pig.73 Vaccination with MLPRV is the 
method of choice for controlling clinically active pseudorabies outbreaks, as it 
will rapidly reduce clinical losses.73 
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There are some potential disadvantages in using modified live vaccines. 
First, reversion to greater virulence during replication in the host animal is a 
potential problem,76 although reversion of MLPRV vaccines has not proved a 
problem in practice.25,73 Second, the excretion of modified live virus is another 
potential hazard,63,73 because it may initiate a series of passages through pigs, 
possibly leading to an increase in virulence of the vaccine virus.25 Excretion of 
MLPRV from pigs vaccinated IM has been reported25 with strains MK-2595 and 
B-KAL 68,90 although a number of researchers have found no evidence of 
excretion using other strains.4,9,25,50,63 Third, unrecognized adventitious or 
contaminating agents may infect the cells in which the vaccine is produced. 
Adventitious viruses includi.ng avian leukosis and other retroviruses, SV-40, 
bovine viral diarrhea virus, and porcine parvovirus have been found in various 
modified live vaccines.73 Fourth, as clinical signs may be seen in pigs following 
.vaccination with MLPRV25 there may be some risk in administering these 
vaccines, particularly to young or pregnant animals. Tolvid® is the only USDA 
licensed vaccine not recommended for pigs less than 3 weeks of age. 73,98 There 
are no reports of reproductive failure in pregnant animals due to MLPRV 
vaccination. Modified live PRV vaccines have varying degrees of safety in 
sheep, cattle, cats, dogs and laboratory animals.73,100 Fifth, there is the potential 
for MLPRV to recombine with other virus strains. The recombination of vaccine 
virus, containing gene deletions, with other viruses is unlikely. However, if it 
occurred it may give misleading resultc: =~ serological diagnostic tests that 
differentiates vaccinated from field infected pigs.73 
10 
Killed Virus Vaccines 
Killed virus vaccines, prepared by inactivating whole virions, generally 
stimulate the development of circulating antibody against viral coat proteins.67 
A number of methods have been reported for the chemical inactivation of PRV 
so it can be used as a killed vaccine.44,49,75,102,112,113 Proper inactivation 
overcomes the disadvantages associated with MLPRV vaccines that stem from 
replication of virus within the host or from contamination of vaccines with 
adventitious agents. 67,73 
A major disadvantage of killed virus vaccines has been that the immunity 
conferred by one dose is often low and of short duration, and a second injection 
must be administered. The use of two doses of KPRV vaccine is recommended 
for adequate protection against virulent PRV in the field.74 Most reports 
indicate that KPRV vaccines are less effective than MLPRV vaccines25,36,63,64 
although identical efficacy has been reported.3,25 
Although there is incomplete knowledge of the factors controlling the 
class and intensity of an immune response, it is influenced by the molecular and 
chemical complexity, dose, and form of administration of the inducing agent, 
and the immunogenic capacity of the responding host.103 The dose of inducing 
agent and the form in which it is administered are two easily controllable 
variables that can be manipulated to improve the immunogenicity of killed 
vaccines.73 The dose of virus used in killed vaccines is a compromise between 
the level of immunity required and the cost of vaccine production. The dose can 
be lowered by effective use of adjuvants and carriers in which the antigen and 
adjuvants are incorporated.52 Adjuvants act nonspecifically to increase specific 
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immune response to an antigen by inducing the production of lymphocytic 
growth factors.2 ,51 There are potential undesirable effects of adjuvants 
including; unacceptable inflammatory or necrotizing reactions at injection sites, 
CNS effects, impairment of growth, arthritis, induction of autoimmune 
responses, and the rendering of food animals unsafe for human 
consumption.1,2,20 Only adjuvants that are both efficacious and lacking in side 
effects can be used in killed virus vaccines. 
Humeral Immune Response 
The humeral immune response of pigs to PRV infection and vaccination 
have been studied extensively using a number of techniques which detect 
circulating antibodies. Some of these tests include: microtitration serum 
neutralization test (SVN),45 microimmunodiffusion test,40 
macroimmunodiffusion test,91 indirect solid-phase microradioimmunoassay 
test,54 indirect immunoperoxidase rnethod,84 radioirnmunoprecipitation 
method (RIP),65,108 complement fixation test,33 latex macroagglutination test,109 
and enzyme-linked immunosorbent assays (ELISA).19,31,35,48,83,92,107 
In PRV infected animals, anti-viral antibodies can be detected by ELISA 
at 5 days post-challenge (PC).83 Up to day 7 PC, these antibodies are almost 
exclusively of the IgM class. IgM titers are still high at day 18 PC but then 
rapidly decrease.61 Antibodies of the IgG class are detectable at day 7 PC,83 
peak at about day 35 PC and remain detectable by ELISA and SVN for an 
extended period.41,61,62,78,83 Low levels of IgA class antibodies are secreted by 
oral and nasal mucosa shortly after PRV infection.10,83 Re-exposure to PRV 
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induces high levels of protective anti-PRV IgA and also a marked circulating 
SVN antibody response.10,11 
Vaccination of pigs with PRV vaccines induces a humeral immune 
response that differs from that observed in natural infection. It has been 
demonstrated using an ELISA that in PRV vaccinated pigs, IgM antibodies 
decline more rapidly, IgG antibodies peak at lower titers, and IgA antibodies 
cannot be detected in oropharyngeal fluids.83 The SVN antibody titers of 
vaccinates are generally lower than those of PRV infected pigs, and there is 
marked variability in the persistence of these antibodies with different PRV 
vaccines.25,27,61,63,64 In some studies, pigs which received 1 dose of a KPRV 
vaccine had higher SVN antibody titers of longer duration than pigs which 
received MLPRV vaccine.64,114 Exposure of vaccinated pigs to PRV produces a 
marked anamnestic SVN antibody response.3,25 
The immunogens of the pseudorabies virion have not been fully 
characterized, however, it is known that glycoproteins induced by PRV 
infection and those ultimately included in the mature enveloped virus are 
immunologically important. There may be significantly lower humeral immune 
response in animals exposed to PRV strains lacking genes coding for some 
glycoproteins. Those glycoproteins that have been identified as immunogens 
include: gpI, glycoprotein II, glycoprotein III, gpX, gpSO, and gp63.32 
Using a gpI ELISA, it has been shown that antibodies to gpI persist in 
pigs for at least 32 week.:: ~'.::: with PRV, and the antibodies can also be detected 
in pigs vaccinated with PRV strains that contain the gene coding for gpI.106 In 
contrast, gpI antibodies have not been reported in pigs vaccinated with PRV 
strains in which there is deletion of the gene coding for gpI (gpI negative).104 
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The use of gpl negative vaccines in combination with culling of gpl antibody 
seropositive infected pigs has achieved elimination of field virus from PRV 
infected herds.104 
Pigs infected with field strains of PRV produce antibodies to gpX 
detectable by HerdChek®: Anti-PRV-gpXf assay.48 The subunit diagnostic 
antigen (SUDA) ELISA and RIP detect antibodies to SUDA, which has a reported 
molecular weight the same as that as gpX. 65 McGinley and Platt detected SUDA 
antibody as early as 14 days after low dose PRV challenge of PRV subunit 
vaccinated pigs. Antibody persisted as long as 113 days PC in 3of10 pigs, but 1 
pig became seronegative by SUDA ELISA as soon as 21 days PC. Eight of these 
10 pigs were shown to be latently infected, and 1 latently infected pig failed to 
produce SUDA antibodies after viral recrudescence. Antibodies to gpX have no 
PRV neutralizing activity and pigs with gpX antibodies alone, are not protected 
from lethal PRV infection.99 Vaccination of pigs with PRV strains, in which 
there is a deletion of the gene coding for gpX (gpX negative), does not induce 
gpX antibody production.48 
Glycoprotein III and gpSO, induce the formation of antibodies which have 
a neutralizing activity in the absence of complement.42,108 Virus neutralizing 
antibody is primarily responsible for neutralizing free virus in the blood and 
tissue fluids. IO The presence of neutralizing antibody, does not prevent 
multiplication or distribution of PRV in tissues of vaccinated pigs challenged 
with PRV, and the range of tissues in which these occur is the same as 
f IDEXX, Incorporated., Portland, Maine. 
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challenged pigs. However, it has been demonstrated that virus titers are lower 
in the first 7 days PC in vaccinated animals.111 
Despite attempts by a number of researchers,21,25,61,110 it has not been 
possible to correlate immunological parameters with the effectiveness of PRV 
vaccines in limiting the clinical sequelae of PRV infection. It would appear that 
the level of protection provided by vaccination is a function of both the humoral 
and cell-mediated immunity induced.5,111 
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SECTION I. DEVELOPMENT OF KILLED VACCINES CONTAINING A 
GPX DELETED STRAIN OF PSEUDORABIES VIRUS 
16 
SUMMARY 
The efficacy of 13 inactivated vaccine preparations containing a 
glycoprotein X (gpX) gene deleted strain of pseudorabies virus (PRV) was 
evaluated by challenging vaccinated pigs intranasally. Experimental vaccines 
contained 1 of 4 adjuvants and varying concentrations of viral antigens. 
Vaccination of pigs with 1 dose of experimental vaccines adjuvanted with 50% 
Montanide ISA 50 or 20% Syntrogen induced a protective immunity at least 
equal to that induced by 2 commercially available killed PRV vaccines also 
evaluated. The serum virus neutralizing antibody titers induced by the 
experimental vaccines containing Montanide ISA 50 were much higher than 
those induced by the commercially avaiable vaccines. None of the experimental 
vaccines induced gpX antibodies, detectable by the HerdChek®: Anti-PRV-gpX 
assay, in vaccinated pigs. Therefore, this assay could differentiate PRV vaccine 
induced antibodies from antibodies induced by natural exposure when used in 
conjunction with these experimental vaccines. 
17 
IN1RODUCTION 
The vaccination of pigs against pseudorabies is commonly practiced.9,17 
Vaccination will not prevent infection with pseudorabies virus (PRV); however, 
it will reduce the duration and severity of clinical signs of pseudorabies and the 
amount of virus shed by infected pigs),4,5,14 Modified live pseudorabies virus 
(MLPRV) vaccines are generally considered to provide greater protection than 
killed pseudorabies virus (KPRV) vaccines,4,8,13,14 even though the antibody · 
titers that are induced by one dose of KPRV vaccine are generally of similar 
magnitude and duration as titers induced by one dose of MLPRV vaccine.4 
Killed PRV vaccines do have some advantages over MLPRV vaccines. A higher 
anamnestic response is induced in sensitized animals with KPRV 
vaccines.4,14,17,21 Also the inactivation of killed vaccines prevents vaccine virus 
from replicating in vaccinated animals. Replication of virus does occur in the 
pig after MLPRV vaccination.J,S,13 There are potential problems that may result 
from vaccine virus replication. Vaccine virus may be excreted,4 leading to a 
series of passages through pigs and possibly an increase in virus virulence by 
genetic mutation or recombination.17 Replication of some MLPRV in pigs 
causes mild clinical signs,4 although it is possible that in young or pregnant 
animals virus replication may produce more severe effects.17 For these reasons, 
KPRV vaccine is considered by many veterinarians as the vaccine of choice for 
boostering immunity, particularly in pregnant sows.17 
A major disadvantage in using KPRV vaccines is that none of the KPRV 
vaccines available in the United States have an accompanying diagnostic test 
that can differentiate antibodies induced by vaccination from antibodies 
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induced by field virus infection. In contrast, pigs vaccinated with the 
commercially available MLPRV vaccine, PRV /Marker®a can be distinguished 
from PRV infected pigs by using the HerdChek®: Anti-PRV-gpX assayb (Anti-
gpX ELISA).12 Specific modifications have been made to the PRV /Marker® 
vaccine virus, including the deletion of the gene coding for glycoprotein X 
(gpX).20 The deletion of this gene acts as a "negative marker." The Anti-gpX 
ELISA is specific for antibodies to gpX and ignores antibody titers in pigs 
vaccinated with PRV /Marker®. However, it detects gpX antibody in pigs 
infected with field strains of PRV.12 The development of a KPRV vaccine that 
does not induce gpX antibody in vaccinated pigs and that could be used in 
conjunction with the Anti-gpX ELISA would be beneficial in eradicating PRV 
from infected herds. 
The purpose of this study was to evaluate inactivated vaccine 
preparations containing a gpX deleted strain of PRV. The virus strain was 
specially developed for this study and provided by SyntroVet.a The type of 
adjuvant and the concentration of viral antigen in vaccine preparations were 
varied to determine the effect these parameters had on the level of immunity 
induced in vaccinated pigs. The level of immunity was evaluated by measuring 
the humoral immune response to vaccination and by comparing the effect that 
intranasal challenge with PRV had on vaccinated and non-vaccinated pigs. 
a Syntro Vet Incorporated, Lenexa, Kansas. 
b IDEXX Incorporated, Portland, Maine. 
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MATERIALS AND METHODS 
General 
Vaccines 
Thirteen experimental vaccine preparations and two commercially 
available vaccines were used. 
Experimental vaccines were supplied by SyntroVet Inc. The SyntroVet 
virus strain was propagated on Vero cells to obtain the viral antigens contained 
in the experimental vaccines. Infected cultures were harvested 48 to 72 hours 
post-infection. The infectivity titer of viral fluids was determined by plaque 
assay6 prior to the inactivation of virus with binary ethyleneimine.2 After 
inactivation, viral fluids were mixed with either 1of4 adjuvants; Emulsigenc, 
Amphigen Based, Montanide ISA soe, or SyntrogenTMa, according to the 
adjuvant manufacturers recommendations.11,16,19 The final concentration of 
viral antigen in vaccine preparations was estimated from the pre-inactivation 
infectivity titers, and expressed as a lX concentration (undiluted viral fluids) or 
the respective fraction of the lX viral fluids. 
The two commercially available KPRV vaccines used, PR-Vac®-Killedf 
and Porci-Rab®g were purchased anonymously. 
All vaccines were administered as a 2 ml dose, intramuscularly (IM) in 
the neck. 
c Modem Veterinary Products Incorporated, Ralston, Nebraska. 
d Hydronics Incorporated, Omaha, Nebraska. 
e Seppic, Paris, France. 
f Norden Laboratories, Lincoln, Nebraska. 
g Beecham Laboratories, Bristol, Tennessee. 
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Animals and Housing 
All pigs were obtained from pseudorabies free herds and housed in 
facilities secure for PRV exposure. 
Challenge virus 
Pseudorabies virus strain VDL 4892 was used to challenge vaccinated 
and non-vaccinated pigs. The virus was propagated and titrated on Madin 
Darby bovine kidney (MDBK) cells. Growth medium consisted of Minimal 
Essential Mediumh (MEM) supplemented with 50 mg/ml gentamycin sulphate, 
2 mg/ml amphotericin Band 10% fetal bovine serum. Maintenance medium 
was MEM supplement with 400 mg/ml streptomycin sulfate, 100 units/ml 
penicillin, 50 mg/ml gentamycin sulfate, 2 mg/ml amphotericin B, 24 units/ml 
tylocine and 2% fetal bovine serum. 
Virus isolation 
Nasal and tonsil swabs and tissue samples were assayed for virus. Nasal 
and tonsil swabs were placed in tubes containing 0.5 mls of Earlesh medium. 
The tube was then vortexed, the swab removed and the tube centrifuged at 3000 
PRM (2000 g.) for 10 minutes. Tissue samples were mascerated in an equal 
volume of Earles medium and centrifuged as described for swabs. Supernatants 
were assayed for PRV by inoculation in MDBK cells which were examined for 
CPE daily for 7 days. Negative cultures were subcultured and observed for 7 
days. Pseudorabies isolates were identified by immunofluorescence. 
h Gibco Laboratories, Grand Island, New York. 
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Antibody assays 
Serum samples were assayed by the serum virus neutralization (SVN) 
test as described by Hill et al.,10 and the Anti-gpX ELISA using the 
recommended procedure.12 
Trial 1 
Vaccines 
Three vaccines containing inactivated SyntroVet virus (KV-SV) were 
used: vaccine lA containing 0.004X viral antigen and 40% Emulsigen/ dose 
(0.004X viral antigen/40% Emulsigen), vaccine lB- 0.012X viral antigen/40% 
Emulsigen, and vaccine IC - 0.04X viral antigen/ 40% Emulsigen. 
Procedures 
Twenty-five pigs, 4 to S weeks of age were randomly assigned to S 
groups of S pigs. Three groups were vaccinated twice at 21 day intervals with 1 
of each of the 3 vaccines. A fourth group received 1 dose of vaccine lB at the 
time of the second vaccination of the other groups. One group remained non-
vaccinated controls. Twenty-one days after the second vaccination, all pigs 
were challenged intranasally with 103.4 PFU of PRV as a 1 ml dose. Clinical 
observations were made, nasal and tonsil swabs collected and rectal 
temperatures recorded daily for 14 days post-challenge (PC). Serums were 
obtained from blood samples collected on the day of vaccination and then 
weekly until 14 days PC. Pigs were weighed 14 days PC. Pigs that died during 
the trial were necropsied and samples were collected for virus isolation. 
22 
Trial 2 
Vaccines 
Three KV-SV vaccine preparations were used: vaccine 2A- O.lX viral 
antigen/20% Emulsigen, vaccine 2B - O.lX viral antigen/20% Emulsigen/67.5% 
Novalep®-si, and vaccine 2C - 0. lX viral antigen/10% Amphigen Base. In 
addition, two commercially available vaccines, PR-Vac®-Killed and Porci-Rab® 
were used. 
Procedures 
Twenty-nine pigs, 4 to 5 weeks of age were randomly assigned to 5 
groups of 5 pigs and 1 group of 4 pigs. Each of the groups containing 5 pigs 
were vaccinated with 1 dose of vaccine and the group of 4 pigs remained non-
vaccinated controls. Forty-two days post-vaccination (PV) all pigs were 
challenged intranasally with 105.8 PFU of PRV as a 1 ml dose. Serums were 
collected on the day of vaccination and then weekly until 14 days PC. Pigs were 
observed for clinicals signs daily for 14 days PC; weighed on the day of 
challenge and day 14 PC; and nasal swabs were collected on days 7, 10 and 14 
PC. Pigs that died during the trial were necropsied and brain, lung, tonsil, and 
spleen samples were collected for virus isolation. 
i Coopers Animal Health Incorporated, Kansas City, Missouri. 
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Trial 3 
Vaccines 
Four KV-SV vaccine preparations were used: vaccine 3A- lX viral 
antigen/30% Emulsigen, vaccine 3B - lX viral antigen/10% Syntrogen, vaccine 
3C - 0.2X viral antigen/10% Syntrogen, and vaccine 3D - lX viral antigen/SO% 
Montanide ISA 50. 
Procedures 
Twenty-five pigs, 3 to 4 weeks of age were randomly assigned to 5 
groups of 5 pigs. Four groups were vaccinated with 1 dose of vaccine and the 
other group remained non-vaccinated controls. Twenty-six days PV pigs were 
challenged intranasally with 1()4.8 PFU of PRV as a 1 ml dose. Serums were 
collected on the day of vaccination and days 7, 14 and 21 PV, and on the day of 
challenge (day 26 PV) and days 7 and 14 PC. Pigs were weighed on the day of 
vaccination, the day of challenge, and day 14 PC. Pigs were observed for 
clinical signs daily for 14 days PC, and nasal swabs were collected on days 3, 6, 
9 and 12 PC. The vaccination site was palpated on days 7, 21, and 40 PV to 
detect any tissue reactions to th~ vaccines. Pigs that died during the trial and 
the pigs vaccinated with preparations containing Montanide ISA 50 were 
necropsied. 
Trial 4 
Vaccines 
Four KV-SV vaccine preparations were used: vaccine 4A- lX viral 
antigen/SO% Montanide ISA 50, vaccine 4B - 0.SX viral antigen/SO% Montanide 
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ISA 50, vaccine 4C - 0.2X viral antigen/50% Montanide ISA 50, and vaccine 4D -
O.SX viral antigen/20% Syntrogen. 
Procedures 
Twenty-five pigs, 3 to 4 weeks of age were randomly assigned to 5 
groups of 5 pigs. Four groups were vaccinated with 1 dose of vaccine and the 
other group remained non-vaccinated controls. Twenty-two days PV pigs were 
challenged intranasally with 1()4.8 PFU of PRV as a 1 ml dose. Serums were 
collected on the day of vaccination and days 7 and 14 PV, and on the day of 
challenge (day 22 PV) and days 7 and 14 PC. Pigs were weighed on the day of 
vaccination, the day of challenge, and day 14 PC. Pigs were observed for 
clinical signs daily for 14 days PC and nasal swabs were collected on days 3, 6, 9 
and 12 PC. The vaccination site was palpated on days 7, 22 and 36 PV. 
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RESULlS 
Trial 1 
Response to vaccination 
A single vaccination with any of the vaccines did not produce detectable 
SVN antibody to PRV within the 21 days prior to a second vaccination or 
challenge. In the 3 groups receiving a second dose of vaccine there was a 
variable SVN antibody response; group averages are shown in Figure 1. 
Antibodies were detectable in most pigs receiving 2 doses of vaccine lA or lC by 
7 days PV, and in all these pigs by 21 days PV. The range of SVN antibody 
titers was from 1:2to1:32. There was a poor SVN antibody response in pigs 
receiving 2 doses of vaccine 18. Only 2 of these pigs had SVN antibodies titers 
by 21 days PV. The Anti-gpX ELISA did not detect gpX antibody in any pig 
prior to, or after vaccination. 
Response to challenge 
Results are summarized in Table 1. Three days after challenge exposure 
control pigs became depressed, had reduced appetite, and fever (1040F). These 
signs worsened over the next 3 days and all pigs had mucous to purulent nasal 
discharge, laryngitis and dyspnoea. At day 5 PC, 1 pig developed signs 
indicative of disturbance of the central nervous system (CNS), which included 
muscle trembling, incoordination, head tilting and ataxia. No control pigs died. 
Recovery from clinical signs began around day 7 PC and was complete by day 
10 PC, except for the pig with CNS dysfunction which continued to have a head 
tilt throughout the trial. Clinical signs in vaccinated pigs were less severe than 
in controls, but present for a similar duration. No vaccinates showed 
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Figure 1. Serum virus neutralizing antibody response in vaccinated pigs in Trial 1. Each 
point is the mean± SEM ( e , • n = 5: o, an= 4) 
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Table 1. Summarized serological and clinical results used to 
evaluate the efficacy of killed pseudorabies virus vaccines 
in Trial 1 
Vaccine 
Parameter 1Ax2 1Bx2 1Cx2 1Bx1 Control 
# Challenged 5 4 5 4 5 
MeanSVN 
antibody 1- 0 1: 5 <2 1: 2 <2 <2 titer at -14 1: 675 1: 724 1: 362 1: 181 1: 48 
PC day 
Mean Anti-
gpX ELISA,- 0 0.99 1.03 1.01 1.15 1.09 
reactivity -14 0.45 0.37 0.36 0.49 0.20 
at PC day 
Mortality % 0 0 20 20 0 
CNS dysfunct. % 0 0 0 0 20 
#Shedding - 3 4/5 3/4 4/5 3/4 5/5 
virus - 7 5/5 4/4 5/5 4/4 5/5 
at -10 4/5 3/4 3/5 3/4 5/5 
PC day -14 0/5 0/4 2/4 1/3 3/5 
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evidence of CNS dysfunction, although 2 died. One pig given 2 doses of vaccine 
lC was observed to be pale on day 10 PC and died on day 11 PC. Necropsy 
revealed a large gastric ulcer with hemorrhage into the stomach. Brain and 
tonsil samples and a nasal swab were assayed for virus but PRV was not 
recovered. A pig given 1 dose of vaccine IB, that had recovered by day 9 PC 
from the clinical signs associated with challenge, become depressed on day 12 
PC and died on day 13 PC. Pseudorabies virus was recovered from the tonsil 
but not the brain or nasal swabs. There was no histological evidence of 
encephalitis in either pig. 
All control pigs shed PRV from day 2 to day 11 PC, and 3 of 5 were still 
excreting the virus at day 14 PC. All vaccinated pigs shed virus PC, with the 
number of pigs shedding virus peaking around day 7 PC. Virus shedding for 
vaccinated pigs was of a shorter duration than for control pigs, although three 
vaccinates were shedding virus 14 days PC. 
The rectal temperatures of vaccinated pigs were significantly lower (P < 
0.05) than those of controls between days 3 to 7 PC, although the duration of 
fever was similar for vaccinates and controls. 
The mean body weight of control pigs was 11 kg lower (P < 0.05) than the 
combined mean body weight for all vaccinates at 14 days PC. 
All vaccines induced some degree of protection against challenge with 
virulent PRV. Compared with control pigs, vaccinated pigs had reduced fever, 
shorter periods of virus shed~::-.~ no signs of CNS dysfunction and greater 
body weight 14 days PC. 
The SVN antibody titers of pigs rose rapidly PC, with the SVN antibody 
titers of vaccinated pigs being significantly higher (P < 0.05) than those of the 
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control pigs 14 days PC. All vaccinated and control pigs were postive by Anti-
gpX ELISA 14 days PC. 
Trial 2 
Response to vaccination 
One dose of the KV-SV vaccines induced SVN antibody titers in only 4 of 
the 15 pigs vaccinated with these vaccines. In contrast all PR-Vac®-Killed 
vaccinates and 4 of 5 Porci-Rab® vaccinates developed SVN antibody, although 
the highest SVN antibody titer was only 1:4. The group geometric mean SVN 
antibody titers are shown in Figure 2. At day 40 PV none of the pigs vaccinated 
with KV-SV vaccines had detectable gpX antibodies, whereas 5 of the 10 pigs 
vaccinated with the commercially available KPRV vaccines were positive by 
Anti-gpX ELISA. 
Response to challenge 
The clinical signs observed in control pigs were more severe than those 
seen in the control pigs in Trial 1, although the duration of clinical signs was 
similar. At day 8 PC, 2 control pigs developed CNS dysfunction which included 
muscle tremors and head tilting. Clinical signs in vaccinated pigs varied 
considerably between and within groups. Table 2 summarizes the results of the 
6 groups. Using a subjective assessment of the clinical signs for each group as a 
whole, the KV-SV vaccinated groups were more severely affected by challenge 
than the PR-Vac®-Killed or Porci-Rab® vaccinated groups, but less affected 
than the control group. However, each of the KV-SV vaccinated groups had 2 
pigs which developed CNS dysfunction. 
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Figure 2. Serum virus neutralizing antibody response in vaccinated pigs in Trial 2. Each 
point is the mean ± SEM (n = 5) 
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Table 2. Summarized serological and clinical results used to evaluate the 
efficacy of killed pseudorabies virus vaccines in Trial 2 
Parameter 2A 2B 
# Challenged 5 5 
MeanSVN 
antibody 1- 0 <2 <2 titer at -14 1: 215 1: 891 
PC day 
Mean Anti-
gpX ELISA1- 0 0.99 1.02 
reactivity -14 0.30 0.33 
atPC day 
Mortality % 20 0 
CNS dysfunct. % 40 40 
#Shedding - 7 3/5 3/5 
virus -10 0/5 0/5 
atPC day -14 0/4 0/5 
Weight gain (kg) 
post-challenge 4.6 - 3.7 
Vaccine 
PR-Vac 
2C -Killed 
5 5 
<2 1: 2 
1: 256 1: 2352 
1.00 0.79 
0.44 0.13 
0 0 
40 0 
4/5 0/5 
0/5 0/5 
0/5 0/5 
0.1 10.8 
Porci 
-Rab Control 
5 4 
<2 <2 
1: 304 1: 45 
0.73 1.00 
0.11 0.33 
20 0 
20 50 
3/5 4/4 
1/4 2/4 
0/4 2/4 
2.4 -3.2 
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One of these pigs which received vaccine 2A died, as did one pig in the 
Porci-Rab® group. At necropsy both pigs had a severe, purulent 
bronchopneumonia with a high population of Pasteurella multocida cultured 
from lung samples. Brain, tonsil, lung and spleen samples from both pigs were 
assayed for virus. Pseudorabies virus was recovered only from the tonsil of the 
pig vaccinated with Porci-Rab®. However, histologically there was evidence of 
moderate lymphocytic perivascular cuffing, focal gliosis and mild neuronal 
necrosis in the brains of both pigs, which was suggestive of viral encephalitis. 
All control pigs shed virus at day 7 PC and 2 were shedding virus at day 
14 PC. Vaccination prevented shedding in the PR-Vac®-Killed group by day 7 
PC, and reduced the number of pigs shedding virus in the other groups. No 
vaccinates were shedding virus at day 14 PC. 
All control pigs lost body weight and as a group had a mean body 
weight loss of 3.2 kg over the 14 days PC. As a group, PR-Vac®-Killed 
vaccinates had the highest (P < 0.05) mean body weight gains PC. In the other 
vaccinated groups there was considerable variation in body weight change 
within groups. 
As in Trial 1 the SVN antibody titers of pigs rose rapidly PC, with the 
SVN antibody titers of vaccinated pigs being significantly higher (P < 0.05) than 
those of the control pigs 14 days PC. However, the presence of SVN antibody 
at the time of challenge of KV-SV vaccinates did not correlate with protection, as 
two of four pigs with SVN antibody titers developed CNS dysfunction PC. All 
pigs were positive by Anti-gpX ELISA 14 days PC. 
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Trial 3 
Response to vaccination 
The group geometric mean SVN antibody responses PV are shown in 
Figure 3. One dose of the KV-SV vaccine containing Montanide ISA 50 (vaccine 
3D) induced SVN antibody titers ranging from 1:16 to 1:32 by day 26 PV. In 
contrast, vaccination of pigs with vaccines 3B and 3C, containing 10% 
Syntrogen, did not induce detectable SVN antibody titers. As in Trials 1and2 
the SVN antibody titers of pigs vaccinated with KV-SV preparations containing 
Emulsigen were low and variable. Vaccinated pigs remained negative on the 
Anti-gpX EUSA. 
Pigs receiving vaccine 3D were ne<=ropsied on day 14 PC. All pigs had 
lesions in the muscle at the site of vaccine injection. Grossly an area of muscle 
1.5 to 3 cm in diameter was pale and firm. When the lesion was cut numerous 
small globules of vaccine residue were evident. Histologically each lesion 
contained numerous residue globules, each encapsulated in connective tissue. 
Vaccination had no effect on weight gain prior to challenge. 
Response to challenge 
Results are summarized in Table 3. All 5 control pigs developed clinical 
signs typical of pseudorabies. Pigs become depressed, had reduced appetite 
and mucous nasal discharge on day 4 PC. These symptoms worsened by day 5 
PC and all pigs showed dyspnoea. Signs indicative of CNS dysfunction 
developed on day 5 PC and 3 pigs had died by~-::~- 6 PC. Histologically, these 
three pigs showed evidence of viral encephalitis and PRV was isolated from the 
brain, lung, spleen and tonsil of all 3 pigs. The 2 surviving control pigs had 
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Figure 3. Serum virus neutralizing antibody response in vaccinated pigs in Trial 3. Each 
point is the mean ± SEM ( o, • n = 5; • , D n = 4 ) 
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Table 3. Summarized serological and clinical results used to 
evaluate the efficacy of killed pseudorabies virus 
vaccines in Trial 3 
Vaccine 
Parameter 3A 38 3C 3D Control 
# Challenged 4 5 5 4 5 
MeanSVN 
antibody 1- 0 <2 <2 1: 2 1:20 <2 titer at -14 1: 16 1: 56 1: 14 1:2048 1: 8 
PC day 
Mean Anti-
gpXEUSA 1- 0 0.91 0.88 0.93 0.85 0.96 
reactivity -14 0.51 0.23 0.16 0.44 0.49 
atPC day 
Mortality % 50 0 0 0 60 
CNS dysfunct. % 50 0 0 0 100 
#Shedding - 3 4/4 4/5 5/5 3/ 4 5/5 
VJIUS - 6 1/4 1/5 0/5 0/4 2/2 
at - 9 0/2 0/5 0/5 0/4 2/2 
PC day -12 0/2 0/5 0/5 0/4 1/ 2 
Weight gain (kg) 
pre-challenge 11.1 11.6 12.6 13.2 15.0 
Weight gain (kg) 
post-challenge 5.8 5.4 5.6 9.0 -1.2 
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muscle tremor, incoordination, head tilting, and convulsions. These 2 pigs 
began recovering by day 8 PC, but they continued to have a head tilt until the 
end of the trial. Pigs receiving vaccine 30 showed the least clinical signs PC. 
These pigs had a slight decrease in appetite and were mildly depressed on day 5 
PC. Clinical signs persisted from day 5 to 7 PC in pigs receiving vaccine 3B and 
3C and they were of similar magnitude to those seen with vaccine 30. The 
response of pigs receiving vaccine 3A was variable. Two pigs showed mild 
clinical signs between days 5 and 7 PC, whereas, the other 2 pigs became 
extremely depressed, developed CNS dysfunction and died by day 7 PC. Both 
the pigs had histological evidence of a viral encephalitis but PRV was not 
isolated from either brain. 
Vaccination markedly decreased the duration of virus shedding PC. Both 
surviving controls shed virus on day 9 PC, whereas, pigs vaccinated with 
vaccine 3C or 30 did not shed virus after day 3 PC and only 1 pig in each group 
receiving vaccine 3A or 3B shed virus at day 6 PC. 
Pigs receiving vaccine 30 had the least severe clinical signs and gained 
significantly (P < 0.05) more weight than pigs in the other treatment groups. 
Vaccinated pigs had a rapid rise in SVN antibody titers PC. Those 
vaccinates that had no detectable SVN antibody response to vaccination still had 
an anamnestic rise in SVN antibody PC, and the pigs vaccinated with vaccine 3B 
or 3C were well protected from challenge. One pig receiving vaccine 3A had an 
SVN antibody titer of 1:4 at the r ::-. .: of challenge but was not protected. 
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Trial 4 
Response to vaccination 
The group geometric mean SVN antibody responses PV are shown in 
Figure 4. One dose of the KV-SV vaccines containing Montanide ISA 50 
induced SVN antibody titers ranging from 1:4to1:32 by day 22 PV. There was 
no evidence to suggest that a change in viral antigen concentration from lX to 
0.2X/ dose had any effect on the SVN antibody response in vaccinated pigs. All 
pigs receiving vaccine 4D (20% Syntrogen) had SVN antibody titers of 1:2 by 
day 22 PV. Vaccinated pigs remained negative on the Anti-gpX ELISA prior to 
challenge. 
Intramuscular swelling at the site of injection was detected by palpation 
in 2 pigs in each of groups 4A, 4C and 4D and 1 pig in group 4B at day 7 PV. At 
day 21 PV, reactions could still be palpated in 4 pigs that had received vaccines 
containing Montanide ISA 50, but by day 36 PV no reactions were detected by 
palpation. 
Vaccination had no apparent effect on weight gains prior to challenge. 
Response to challenge 
Results are summarized in Table 4. All control pigs developed clinical 
signs typical of pseudorabies. Signs indicative of CNS dysfunction were evident 
in all pigs by day 6 PC. The severity of signs varied from trembling and slight 
incoordination in 1 pig, to ataxia, head tilting, and convulsions in the 2 most 
severely affected pigs. All control pigs survived and began recovering by day 8 
PC although 2 pigs continued to head tilt until the end of the trial. Only 2 
vaccinated pigs showed any clinical signs in the 14 days PC. One pig receiving 
vaccine 4A was depressed, trembled and circled aimlessly on day 9 PC. The 
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Figure 4. Serum virus neutralizing antibody response in vaccinated pigs in Trial 4. Each 
point is the mean± SEM (n = S) 
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Table 4. 
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Summarized serological and clinical results used to 
evaluate the efficacy of killed pseudorabies virus 
vaccines in Trial 4 
Vaccine 
Parameter 4A 4B 4C 4D Control 
# Challenged 5 5 5 5 5 
MeanSVN 
antibody 1- 0 1: 7 1: 12 1: 8 1: 2 <2 titer at -14 1: 776 1: 1176 1: 1783 1: 294 1: 24 
PC day 
Mean Anti-
gpX ELISA,- 0 0.95 0.92 0.97 1.07 0.94 
reactivity -14 0.80 0.45 0.37 0.38 0.30 
at PC day 
Mortality % 0 0 0 0 0 
CNS dysfunct. % 20 0 0 0 100 
#Shedding - 3 0/5 0/5 1/5 5/5 5/5 
virus - 6 0/5 0/5 0/5 0/5 5/5 
at - 9 0/5 0/5 . 0/5 0/5 5/5 
PC day -12 0/5 0/5 0/5 0/5 4/5 
Weight gain (kg) 
pre-challenge 7.0 8.4 8.7 8.4 7.7 
Weight gain (kg) 
post-challenge 5.5 7.0 6.2 5.3 0.6 
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signs of CNS dysfunction were absent by day 10 PC and the pig had recovered 
by day 12 PC. Necropsy on day 14 PC revealed no gross abnormalities. 
Histologically there was lymphocytic perivascular cuffing in the brain 
suggestive of a viral encephalitis,however, PRV was not isolated from the brain. 
One pig receiving vaccine 40 was slightly depressed on days 6 and 7 PC but 
showed no other clinical signs. 
Virus was shed by all control pigs on days 3, 6, and 9 PC and 4 of the 5 
controls on day 12 PC. In contrast, PRV was only isolated from vaccinated pigs 
on day 3 PC and this was limited to the 5 pigs receiving vaccine 40 and 1 pig 
receiving vaccine 4C. 
Control pigs as a group had only a minimal gain in body weight in the 14 
days PC. The weight gains of vaccinated pigs were significantly (P < 0.05) 
higher than those of control pigs and there was no evidence to suggest there 
were any differences in weight gain between vaccinated groups. 
The timing of the anamnestic SVN antibody response varied between 
vaccinated pigs. At day 7 PC there was at least a 4-fold increase in SVN 
antibody titers in all 5 pigs receiving vaccine 40 (20% Syntrogen). The SVN 
antibody response in pigs receiving Montanide ISA 50 vaccines ranged from no 
change in 4 pigs up to a change similar to that seen in the Syntrogen vaccinates. 
By day 14 PC the group mean SVN antibody titers of groups 4A,4B,and4C were 
similar and much higher than that of the Syntrogen group. Four pigs all in 
group 4A (1X viral antigen/SO% Montanide ISA 50), remained negative by the 
Anti-gpX ELISA at day 14 PC, although there was evidence to suggest low 
levels of antibodies to gpX were present in the serums of these pigs. The slow 
anamnestic SVN antibody response, the low levels of gpX antibody detected, 
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and the failure to isolate the challenge virus from these pigs suggests there was 
limited replication of PRV in these pigs PC. At day 21PC,3 of these 4 pigs were 
positive by the Anti-gpX ELISA. 
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DISCUSSION 
The SVN antibody response by pigs after IM inoculation with vaccines 
containing KV-SV was more dependent on the type and concentration of 
adjuvant than on the amount of virus antigen used in each preparation. 
Vaccines adjuvanted with Montanide ISA 50 induced significantly (P < 
0.05) higher SVN antibody titers than vaccines containing other adjuvants. In 
Trial 3, vaccines containing Emulsigen or Syntrogen induced group geometric 
mean SVN antibody titers of <1:2 by day 26 PV, whereas the Montanide ISA 50 
vaccine containing the same amount of PRV antigen induced a group geometric 
mean SVN antibody titer of 1:20. The vaccine in Trial 2 containing Amphigen 
Base also induced a poor SVN antibody response. 
It was possible to alter the immunogenicity of vaccines by varying the 
concentration of adjuvant. In Trial 3, vaccines containing 10% Syntrogen did 
not induce detectable SVN antibody, whereas the 5 pigs in Trial 4 receiving 
vaccine 40, containing twice the concentration of this adjuvant, were all positive 
by the SVN test at day 22 PV. 
Varying the PRV antigen concentration of KV-SV vaccines had only a 
slight effect on the induction of a SVN antibody in vaccinated pigs. In Trial 3 a 2 
log1o increase in pre-inactivation infectivity titer of Emulsigen vaccines caused a 
variable increase in SVN antibody titers. In Trial 4 a reduction in infectivity titer 
by 0.7 log10/ dose of Montanide ISA 50 vaccines caused no change in SVN 
antibody response at day 22 PV. There may not be a linear relationship between 
infectivity titers and PRV antigen concentration of the inactivated vaccines, as 
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the total PRV antigen present may include defective virus particles and debris 
from infected cells, in addition to infective virus particles. 
Vaccination with PR-Vac®-Killed or Porci-Rab® induced low and 
variable SVN antibody titers in pigs. In addition, 50% of these vaccinates were 
positive by the Anti-gpX ELISA. In contrast, all pigs vaccinated with KV-SV 
vaccines remained negative by the Anti-gpX ELISA and there was no evidence 
to suggest there was any difference in the Anti-gpX ELISA reactivity between 
non-vaccinated and vaccinated pigs. Therefore, the Anti-gpX ELISA could be 
used in conjunction with KV-SV vaccines to differentiate PRV vaccine induced 
antibodies from antibodies induced by natural exposure. 
The SVN antibody titer induced by vaccination has little predictive value 
on the degree of protective immunity provided by PRV vaccines.4 Vaccine 
efficacy is best evaluated by comparing the effects that challenge exposure to 
virus has on vaccinated and control animals under standard laboratory 
conditions. By measuring mortality, the development of CNS dysfunction, 
weight gains, fever and virus shedding in vaccinated pigs, PRV vaccines can be 
effectively compared.4 If vaccines are tested at different times, meaningful 
comparisons can still be made if a standard response in control pigs is achieved. 
For PRV vaccines, a challenge dose of virus sufficient to cause CNS dysfunction 
in 80% of control pigs is desired. The severity of clinical signs following 
challenge exposure depends on the virulence of the viral strain, the age of the 
pigs, dose of virus, and route of exposure.9 There have been no previous 
reports on the use of PRV strain VOL 4892 for challenge exposure of pigs. 
Therefore, the dose of challenge virus used initially was based on reports of the 
use of other PRV strains to challenge pigs intranasally),4,9,14 The dose of virus 
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was changed with successive trials until an acceptable dose for the age of pigs 
being used was obtained in Trials 3 and 4. 
The KV-SV vaccines containing Montanide ISA 50 and Syntrogen 
conferred good protection against challenge with PRV strain VDL 4892. 
Although, the depression and reduced appetite seen in some pigs PC indicates 
that all vaccinates were not completely protected. Virus shedding from 
vaccinated pigs PC was of much shorter duration than from control pigs. Virus 
shedding PC by pigs vaccinated with commercially available PRV vaccines has 
been reported to last up to 8 days PC.3 The duration of shedding by pigs 
vaccinated with Montanide ISA 50 or Syntrogen KV-SV vaccines compares 
favorably with this. In Trial 4, virus shedding could be detected in only 1 pig 
receiving a Montanide ISA 50/KV-SV vaccine and no vaccinates shed virus after 
day 3 PC. 
Vaccination had pronounced effects on the growth rate of pigs PC. Pigs 
receiving PR-Vac®-Killed or KV-SV vaccines containing Montanide ISA 50 or 
20% Syntrogen had comparable growth rates that were significantly (P < 0.05) 
higher than growth rates of control pigs. Vaccines containing a lower 
concentration of Syntrogen were slightly less effective. The development of 
body weight PC is considered an important parameter for evaluating vaccine 
efficacy because it is an objective indicator of severity of illness and is directly 
related to economic losses.4 This parameter was used for vaccine evalution in 
Trials 2, 3 and 4, in preference top~:-:.:,.:! of fever, because it revealed the most 
pronounced differences between vaccinated and control pigs. 
As the mortality, percent of pigs with CNS dysfunction and weight gains 
of control pigs PC varied between trials, inter-trial comparisons of vaccine 
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efficacy needs to be done with care. Nevertheless, it seems reasonable to group 
the KV-SV vaccines into 3 categories according to their levels of efficacy: (i) the 
least effective were vaccines containing Emulsigen or Amphigen Base (vaccines 
lA, IB, IC, 2A, 2B, 2C and 3A); (ii) vaccines containing 10% Syntrogen (vaccines 
3B and 3C) were of moderate efficacy, (iii) vaccines containing Montanide ISA 
50 (vaccines 3D, 4A, 4B and 4C) or 20% Syntrogen (vaccine 4D) gave the best 
protection. The 2 commercially available vaccines used in Trial 2, PR-Vac® 
Killed and Porci-Rab® would be in categories (iii) and (i) respectively. 
The efficacy of vaccines 3D, 4A, 4B, 4C and 4D would make them suitable 
for use as killed vaccines against pseudorabies. However, factors such as cost, 
safety, stabilitiy and licensing difficulties need to be considered prior to making 
a decision on which vaccine would be best for commercial production.18 
Adjuvants added to veterinary vaccines must meet standards of purity, be 
nontoxic, not denature specific substances in the product through the dating 
period, and also not leave harmful residues in meat.7 
Montanide ISA 50 is an an oil based adjuvant. The immunoenhancing 
effects of oil are related to its protection of antigens from host degradation, the 
transport of antigens through the lymphatic system where foci of antibody 
production can be established, and the progressive release of antigens from the 
site of injection.15 The manufacturer of Montanide ISA 50 reports that the 
product stimulates the immune response to many viral antigens and that foot-
and-mouth vaccines containing Montanide ISA have been used successfully in 
South America.16 However, there are no reports of its use in USDA licensed 
vaccines. One disadvantage identified in the study was the IM reaction at the 
site of injection. This localized reaction consisting of fibrous tissue containing 
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small cyst-like spaces filled with emulsion is not uncommon with oil adjuvants 
but may be an obstacle to USDA licensing. One other disadvantage of the 
vaccines adjuvanted with Montanide was that they were viscous and difficult to 
inject through an 18 gauge needle. A major advantage of vaccines 3D, 4A, 4B 
and 4C (50% Montanide ISA 50) over vaccine 4D (20% Syntrogen) was that they 
induced much higher SVN antibody titers. Vaccines that induce high antibody 
levels in the colostrum of sows, so that newborn piglets receive high maternal 
immunity, may be preferable. 
Finally, the economic aspects are an important determinate on the choice 
of PRV vaccines. The relative costs of vaccine production with Montanide ISA 
50 and Syntrogen would need to be evaluated prior to selecting which of the 
KV-SV vaccines was best suited for commercial production. 
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SECTION II. EVALUATION OF 1HE PSEUDORABIES ANTI - GPX ELISA 
TEST 
51 
Sillv1MARY 
The persistence of antibodies to glycoprotein X (gpX) in the serum of pigs 
experimentally infected with pseudorabies virus (PRV) was determined using 
the HerdChek®: Anti-PRV-gpX assay (Anti-gpX ELISA). Antibodies to gpX 
were detected for at least 365 days post-challenge in non-vaccinated pigs. 
Previous sensitization of pigs by vaccination with PRV /Marker® had no 
apparent effect on the antibody response of pigs to gpX post-challenge. In 
determining previous exposure of pigs to PRV strains containing the gpX gene, 
the Anti-gpX EUSA was highly specific, but its sensitivity was lower than the 
standard serological procedures currently used for detecting PRV antibodies. 
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INTRODUCTION 
The move toward a national pseudorabies eradication program has 
dictated a need for improved diagnostic tests. Of particular importance has 
been the need for a diagnostic serology test that would differentiate vaccinated 
pigs from infected pigs. Vaccination of pigs with pseudorabies virus (PRV) 
vaccines is commonly practiced. Vaccination will reduce mortalities, shorten 
growth arrest periods, and decrease the shedding of virulent PRV after 
challenge.1 Vaccination will not prevent infection or the establishment of latent 
infection with virulent virus.7 Therefore, PRV exposure following vaccination 
needs to be assessed, but, standard serological procedures are of limited value 
since they cannot distinguish antibodies induced by natural infection from those 
induced by PRV vaccines. Considerable effort has been directed at this problem 
as the inability to differentiate these antibody responses markedly decreases the 
efficiency of eradication programs utilizing vaccination. The creation of gene 
deleted vaccines and their associated diagnostic tests are major breakthroughs 
in overcoming the problem with conventional vaccines and standard serological 
procedures. 
Genetically engineered PRV vaccines have deletions of non-essential 
genes. One example is the deletion of the gene coding for glycoprotein X (gpX), 
which is secreted by PRV infected cells. Glycoprotein Xis a major antigen 
interacting with an infected pig's immune system.4 However, antibodies to gpX 
have no PRV neutralizing activity so the deletion of the gpX gene does not 
reduce the efficacy of the vaccine.5 Two USDA licensed gpX deleted vaccines 
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are available, PRV /Marker®a and Tolvid®b. Both vaccine strains also have the 
gene coding for thymidine kinase (TK) deleted from their genomes. The 
deletion of the TK gene reduces vaccine virulence and the likelihood of the 
establishment of latent infection with the vaccine strain.8 
PRV /Marker® has an accompanying USDA licensed diagnostic test, the 
HerdChek®: Anti-PRV-gpxc (Anti-gpX EUSA), which is specific for antibodies 
to gpX in pig serum.3 It ignores antibody titers in animals vaccinated with 
PRV /Marker®, but detects antibody in animals infected with field strains or 
vaccinated with strains that contain the gpX gene. 
The major objectives of this study were to determine the persistence of 
antibodies to gpX in non-vaccinated and PRV /Marker® vaccinated pigs 
following PRV infection, and to compare the Anti-gpX EUSA with the standard 
serological procedures used to assess PRV exposure. 
a SyntroVet Incorporated, Lenexa, Kansas. 
b The Upjohn Company, Kalamazoo, Michigan. 
c IDEXX Incorporated, Portland, Maine. 
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MATERIALS AND METHODS 
Trial I 
Four 8 week old pigs from a PRV negative herd were challenged 
intranasally with 1()5.0 plaque forming units (PFU) of the Shope strain of PRV. 
Serums were collected on the day of challenge and 48 times over the next 365 
days. 
Trial II 
Three groups of 5 pigs, 6 to 8 weeks of age, from a PRV negative herd 
were used. Group A remained non-vaccinated controls. Group B received one 
dose of PRV /Marker® intramuscularly (IM) according to the manufacturers 
instructions. Group C received 10 times the manufacturers recommended dose 
of PRV /Marker® IM. All pigs were challenged intranasally with 103.0 PFU of a 
virulent strain of PRV, VDL 4892, 10 weeks post-vaccination (PV). Serums were 
collected from all pigs on the day of vaccination, days 14, 62, and 66 PV, the day 
of challenge, and days 3, 7, 10, 14, 21 and 28 post-challenge (PC). To determine 
the persistence of antibodies to PRV, Group B was also bled on days 42, 53, 67, 
and 115 PC. 
Test Serums 
A total of 1,372 pig serums were assayed. These were divided into 6 
groups. Included in these groups were pig serums utilized in Trials I and II. 
Group l Serums from 1,017 non-vaccinated pigs originating from 
PRV negative herds (no clinical or serological evidence of PRV infection). 
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Group i Serums from 157 pigs vaccinated with 1 or 2 doses of 
PRV /Marker® and bled 3 weeks PV. 
Group J Serums from 35 pigs vaccinated with 1 or 2 doses of 
Tolvid® and bled 3 weeks PV. 
Group ,1: Serums from 60 pigs vaccinated with killed or modified live 
gpX positive PRV vaccines and bled 3 weeks PV. 
Group .2 Serums from 48 pigs infected intranasally with PRV strain 
VDL 4892, and bled 2 to 4 weeks PC. 
Group§ Serums with varying virus neutralizing antibody titers from 
55 non-vaccinated pigs from PRV infected herds. 
Assays 
Serums were tested with the Anti-gpX ELISA, the HerdChek®:. Anti-PRV 
(S)c (Anti-PRV ELISA), the serum virus neutralization (SVN) test, and by 
radioimmunoprecipitation (RIP). 
The Anti-gpX ELISA is a competitive enzyme immunoassay, utilizing 
monoclonal antibodies that are specific for gpX. The manufacturer describes the 
principles of the test in the kit insert3 as follows: The Anti-gpX ELISA is 
performed in a PRV antigen coated microwell using a two-fold (1:2) serum 
dilution. During the first incubation, PRV antibodies present in the serum, 
including those produced against gpX, react with antigens on the plastic. 
Subsequent to a wash step, an anti-gpX monoclonal antibody conjugate is added 
to the microwell and is allowed to compete for the gpX viral antigen during a 
second incubation. If no gpX antibodies are present in the test serums, the 
conjugated gpX antibodies are free to react with the gpX antigen. Conversely, if 
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gpX antibodies are present in the test serum, the enzyme-conjugated 
monoclonal antibodies are blocked from reacting with the antigen. Following 
this incubation period, the unreacted conjugate is removed by washing and a 
substrate/ chromagen solution is added. In the presence of enzyme, the 
substrate is converted to a product which reacts with the chromophore to 
generate a blue color. The absorbance at 650 nm A(650), is measured by a 
spectrophotometer. Results are calculated by dividing the A(650) of the sample 
by the mean A(650) of the negative control, resulting in a S/N value. The 
quantity of antibodies to gpX is inversely proportional to the A(650) and, thus, 
to the SIN value. If the S/N is less than or equal to 0.70, the test is classified as 
positive for antibodies to the gpX antigen of PRV. If the S/N is greater than 0.70 
the test is classified negative. The presence of PRV antibodies, including anti-
gpX, indicates a previous exposure to a field strain of PRV, or application of 
conventionally modified live or killed virus vaccines. The presence of PRV 
antibodies detected by the Anti-PRV ELISA and/ or SVN test, but absence of 
antibodies to gpX antigen as assessed by the Anti-gpX ELISA indicates a 
response to a gpX deleted vaccine. 
The Anti-PRV ELISA is a commercially available indirect enzyme 
immunoassay used as a screening test for PRV antibodies.9 The presence, or 
absence, of antibody is determined by calculating the sample absorbance to 
weak positive absorbance (S/P) ratio. Serum samples with S/P ratios of less 
than 0.40 are classified negative for PRV antibodies. If the S/P ratio is greater 
than or equal to 0.40 the sample is classified positive for PRV antibodies. 
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Serum virus neutralization titers were determined as described by Hill et 
al.2 The SVN test is the standard serological test used to detect antibody to 
PRV. 
Radioimmunoprecipitation using (355) methionine-labelled subunit 
diagnostic antigen (SUDA) combined with selected serums was performed as 
described by McGinley and Platt.6 
58 
RESULTS 
Trial I 
Prior to challenge, the 4 pigs were serologically negative by Anti-PRV 
ELISA and Anti-gpX ELISA. After challenge the pigs developed positive 
reactions to both tests. Group Anti-PRV ELISA values were above the positive 
threshold by day 8 PC and peaked at day 280 PC (Figure 1). Anti-gpX ELISA 
values were positive by day 8 PC and peaked at day 300 PC (Figure 2). 
Considerable variation in antibody response was seen between individual pigs, 
despite being from the same litter. However, all pigs remained positive on both 
tests from day 8 to day 365 PC. 
Trial II 
All 15 pigs were serologically negative for PRV antibodies at the 
commencement of the trial. Anti-PRV ELISA values for pigs in Groups Band C 
were positive 14 days PV and remained positive throughout the trial. Anti-gpX 
ELISA values remained negative PV and pre-challenge. The group mean Anti-
PRV ELISA and Anti-gpX ELISA values from day 0 to 28 PC are shown in Table 
I. All control pigs were Anti-PRV ELISA and Anti-gpX ELISA positive from day 
10 to 28 PC. The Anti-gpX ELISA values for all vaccinates were positive by day 
21 PC and remained positive until day 115 PC for the 5 pigs in Group B. The 
mean Anti-gpX ELISA values for Group Bare shown in Figure 2. Anti-PRV 
ELISA values for Val.l.:mates increased PC and peaked at day 28 PC. The mean 
values for Group Bare shown in Figure 1. There was little variation in Anti-
PRV ELISA or Anti-gpX ELISA reactivity in non-vaccinated pigs, however, 
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Figure 1. Development and persistence of anti-gpX antibody in non-vaccinated and PRV /Marker® 
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Table 1. Anti-gpX ELISA and Anti-PRV ELISA group mean reactivities 
from day 0 to day 28 post-challenge for the groups in Trial II 
Day post- Group A Group B 
challenge non-vaccinates 1 x PRV /Marker® 
~a PRVh ~ PRV 
0 1.08 0.03 0.92 2.31 
3 1.20 0.00 0.99 2.25 
7 1.09 0.05 1.19 2.45 
10 0.40 1.30 0.81 3.16 
14 0.19 2.11 0.68 3.29 
21 0.26 2.61 0.31 3.31 
28 0.07 3.01 0.11 3.33 
a Anti-gpX ELISA S/N ratios > 0.70 are nega tive. 
b Anti-PRV ELISA S/P ratios> 0.40 are positive. 
Group C 
10 x PRV /Marker® 
~ PRV 
1.10 2.18 
1.06 1.94 
0.84 2.83 
0.83 3.25 
0.30 3.05 
0.26 3.29 
0.18 3.15 
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reactivity in non-vaccinated pigs, however, vaccinated pigs with similar Anti-
PRV ELISA reactivity had considerable variation in Anti-gpX ELISA reactivity 
PC. 
Evaluation of Serological Tests 
The distribution of Anti-PRV ELISA and Anti-gpX ELISA results in the 6 
groups is shown in Table 2. Pigs in Group 1 (non-vaccinated, non-infected) 
were classified as negative by both assays with a high degree of accuracy. 
Antibodies to gpX were detected in none of the PRV /Marker® vaccinated pigs 
and one of the Tolvid® vaccinated pigs 3 weeks PV, whereas, all of these gpX 
deleted vaccinated pigs tested were positive by the Anti-PRV ELISA. The Anti-
gpX ELISA was less sensitive than the Anti-PRV ELISA at detecting pigs 
exposed to gpX positive strains of PRV either by vaccination, experimental 
intranasal inoculation, or by natural infection. Twenty-five of 141 pigs positive 
by Anti-PRV ELISA were negative by Anti-gpX ELISA These 25 pigs had Anti-
PRV EUSA S/P ratios ranging from 0.84 to 3.22. Fifteen of the pigs had SVN 
titers <2 and the other 10 pigs had titers of either 1:2 or 1:4. 
The overall distributions of Anti-gpX EUSA reactivity for Group 1 and 
Groups 2 and 5 are shown in Figures 3 and 4 respectively. The S/N values of 
non-vaccinated pigs (mean= 0.98, standard deviation= 0.12) were significantly 
(P < 0.05) higher than those of PRV /Marker® vaccinated pigs (mean= 0.95, 
standard deviation= 0.10). However the means of both groups were well above 
the positive threshold and there was little deviation from mean reactivity in 
either group. 
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Radioimmunoprecipitation was performed on pooled serum samples of 
pigs in Group 1, Group 2 and Group 3 and on the serum sample in Group 3 
reacting on the Anti-gpX ELISA. The SUDA did not react with antibodies in 
any of the serums tested, but did react with antibodies in control serum from 
PRV infected pigs. The monoclonal antibody to gpX used in the Anti-gpX 
ELISA also reacted with SUDA suggesting SUDA is the same as gpX. 
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Table 2. Results of Anti-gpX ELISA and Anti-PRV ELISA on test serums 
Frequency of Anti-gpX Frequency of Anti-PRV 
Group ELISA results ELISA results 
neg pos neg pos 
Group 1 
(non-vaccinated) 1015 2 912 0 
Group 2 
(PRV /Marker®) 157 0 0 90 
Group 3 
(Tolvid®) 34 1 0 35 
Group 4 
(conventional vaccine) 33 17 12 38 
Group 5 
(PRV challenge) 1 47 0 48 
Group 6 
(infected herd) 3 52 0 55 
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DISCUSSION 
Using a S/N ratio of 0.70 as the positive/negative threshold, the Anti-
gpX ELISA is highly specific for evaluating the exposure of pigs to PRV strains 
coding for gpX. All pigs vaccinated with PRV /Marker® and 34 of 35 pigs 
vaccinated with Tolvid® were negative on this test. The 1 pig vaccinated with 
Tolvid® that was positive by Anti-gpX ELISA was negative by RIP. This 
suggests the gpX antibodies were not present in the serum of this pig and the 
the positive reaction on the Anti-gpX ELISA was due to non-specific 
competition with the conjugated monoclonal antibody to gpX. The lower S/N 
values for PRV /Marker® vaccinated pigs as compared to non-vaccinated pigs 
does not appear to be due to the production of gpX antibodies by PRV /Marker® 
vaccinates. A second vaccination with PRV /Marker® did not induce an 
anamnestic response detectable by the Anti-gpX ELISA, and pooled serums 
from PRV /Marker® vaccinated pigs were negative by RIP. It is likely that the 
binding of other PRV antibodies to the PRV antigen coated microwell caused 
slight steric hindrance to the binding of the conjugated anti-gpX monoclonal 
antibody. Regardless, PRV /Marker® serums were found to show relatively 
little deviation from mean reactivity and were well separated from the S/N 
ratios found among serums from pigs tested 2 to 4 weeks after PRV challenge. 
As all field strains of PRV tested code for gpXIO, the Anti-gpX ELISA can 
effectively distinguish between naturally infected and vaccinated pigs if a gpX 
deleted vaccine has been used. However, currently the Anti-gpX ELISA can 
officially only be used to differentiate animals vaccinated with PRV /Marker® 
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because the license for a diagnostic test is restricted for use with its companion 
vaccine. 
The ELISA discrimination endpoint chosen to distinguish positive and 
negative serums requires a compromise between an assay's sensitivity and 
specificity. The high specificity of the Anti-gpX ELISA was associated with 
some loss of sensitivity as compared to the Anti-PRV ELISA. This lower 
sensitivity means the Anti-gpX ELISA would be less effective than the Anti-PRV 
ELISA as a screening test for detection of antibody to PRV in pig serums. 
However, when used as a monitoring test subsequent to using a gpX deleted 
vaccine, the Anti-gpX ELISA is superior to the Anti-PRV ELISA which is of 
limited value in assessing PRV infection following vaccination, since it cannot 
distinguish between naturally infected and vaccinated pigs. 
For the Anti-gpX ELISA to be an effective assay it needs to detect PRV 
antibodies in PRV exposed pigs, both non-vaccinated and vaccinated, for 
extended periods. This study demonstrated that positive levels of gpX antibody 
are detectable for at least 365 days and 115 days PC, in non-vaccinated and 
PRV /Marker® vaccinated pigs respectively. The sensitization of vaccinates 
with a live PRV gpX deleted vaccine did not significantly alter a pig's humeral 
immune response to gpX when exposed to wild type PRV. Antibodies to gpX 
were detectable earlier PC in non-vaccinates, probably as a result of greater viral 
replication in these pigs. However, by 21 days PC all vaccinates were positive 
by Anti-gpX ELISA and the level of antibody response was similar between 
groups. In Trial II the greater variation in Anti-gpX ELISA reactivity in 
vaccinated pigs as compared to control pigs is unexplained. Importantly, 
however, all vaccinates remained Anti-gpX ELISA positive PC. 
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Pigs from Trial 1 were not assayed to determine if any were latently 
infected with PRV. However, the peaks and troughs in Anti-gpX ELISA 
reactivity over time and the fact that the greatest group mean reactivity of both 
assays did not occur until 9 months PC is suggestive of latent infection with 
recrudescence. 
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